2019 American Transplant Congress
CMV Risk Status Remains a Relevant Risk Factor for Long-Term Outcomes
*Purpose: Intensification of immunosuppression using T cell depleting induction has reduced rates of acute cellular rejection after kidney transplantation. Belatacept, a first in class T…2019 American Transplant Congress
Comparison of Two Dosing Regimens of Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients
Michigan Medicine, Ann Arbor, MI
*Purpose: Significant controversy surrounds the optimal dose and duration of valganciclovir (VGCV) to prevent CMV in high-risk (D+/R-) liver transplant (LT) recipients. High doses cause…2019 American Transplant Congress
The Natural History and Time to Seroconversion of CMV in the Era of Post-Transplantation Chemoprophylaxis: A Single Center Study
Division of Infectious Diseases, University of Arizona, Tucson, AZ
*Purpose: The current cytomegalovirus (CMV) guidelines in solid organ transplantation recommend chemoprophylaxis (ppx) in post-kidney transplantation recipients. This approach has led to a reduction in…2018 American Transplant Congress
Viral-Specific Cytotoxic T-Cell (Viral-Tc) Responses in Highly-HLA-Sensitized Patients (HS) Maintained on Tacrolimus and Everolimus Post-HLAi Kidney Transplant
Introduction: Viral infections represent significant infectious complications post- kidney transplant which may be increased with desensitization. CMV, EBV and BKV infections are the most prevalent.…2018 American Transplant Congress
CMV and BKV Infections after Kidney Transplantation: Combined Tacrolimus/everolimus Strategy Using Antithymocyte Globulin Induction
Cytomegalovirus (CMV) and BK Virus (BKV) infections are frequent complications after kidney transplantation. A combined regimen of calcineurin inhibitor (CNI) and mTOR inhibitors (mTORi) reduces…2018 American Transplant Congress
Altered Function of Cytomegalovirus Specific T Cells in Transplant Recipients
1Stanford U, Stanford, CA; 2U Pennsylvania, Philadelphia, PA; 3VA Palo Alto, Palo Alto, CA.
Background: Cytomegalovirus (CMV) reactivation is associated with increased morbidity and mortality in transplant recipients. CMV establishes latency for the host's lifetime and frequently reactivates. Immunosuppression,…2018 American Transplant Congress
Clinical Significance of Tacrolimus Trough Level at the Early Period after Kidney Transplantation
Background:The stable immunosuppressant level at the early period after kidney transplantation (KT) is one of the most important factors to decide the prognosis of KT.…2018 American Transplant Congress
The TRANSFORM Study: Infection Outcomes with Everolimus Plus Reduced Calcineurin Inhibitor and Mycophenolate Plus Standard Calcineurin Inhibitor Regimens in De Novo Kidney Transplant Recipients
TRANSFORM Study Group, Novartis Pharma AG, Basel, Switzerland.
Purpose: Post-transplant (Tx) bacterial and viral infections are known to affect graft and patient survival. Accumulating evidence supports the protective effect of everolimus (EVR) against…2018 American Transplant Congress
Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients is Associated with Prolonged Cold Ischemic Time of Seropositive Donor Organs
Introduction: Human Cytomegalovirus (CMV) infection is still a major risk factor for immunocompromised patients, e.g. kidney recipients. Based on the CMV serostatus of donor (D)…2018 American Transplant Congress
Clinical Utility of CMV-Specific CD8+ T-Cell Immune Competence Score in Lung and Heart-Lung Transplant Recipients at Risk of Cytomegalovirus Infection
Introduction: Cytomegalovirus (CMV) is a common infection that causes significant morbidity among lung and heart-lung (LHL) transplant recipients. We determined the clinical utility of global…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 33
- Next Page »